Tweets
Indications Awaiting
In the latest podcast, Dr. Jack Cush reviews the latest news, journal reports, regulatory approvals, plus 3 new cases from rheumatologists.
https://t.co/1amiQrCEWX https://t.co/YR0YSDJSg3
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 7 months ago
Food for Thought: "ITIS" Diet for Patients with Rheumatoid Arthritis
https://t.co/C7eTPpNyXj https://t.co/G42sbDskGW
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 7 months ago
NSAIDS Prevent Heart Attacks in PsA
https://t.co/QkJJOyK7o4 https://t.co/VDBCDHPDZ5
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 7 months ago
CNS Dysfunction & Blood Brain Barrier Leakage in SLE
Dr. Jack Cush reviews the ACR21 Plenary Session presentation showing half of lupus patients have cognitive deficits and that these can be correlated with brain abnormalities including BBB permeability.
https://t.co/HoEhqkhVlc
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 7 months ago
ICYMI: Tofacitinib 1st JAK Inhibitor Approved for Ankylosing Spondylitis
The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced.
https://t.co/nkMJUfHF6r https://t.co/cIUMVtDIKd
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 7 months ago
ICYMI: RESTORE trial: yet another failure for PRP injections for knee #OA. Study of 288 Knee oA over 50 years - knee pain scores of −2.1 vs −1.8 on an 11-point scale (range, 0-10) and no difference between PRP and PBO at 12 moshttps://bit.ly/3p6GMf5
Dr. John Cush @RheumNow ( View Tweet )
4 years 7 months ago
ICYMI: NEJM Clinical Images - Tongue Necrosis in Giant Cell Arteritis. 74-yoF w/ 3-day hx of HA and tongue swelling/pain, & blindness in the right eye. Tongue was ulcerated, R temporal artery thickened. ESR 42 CRP 169 mg/L. Read rest of story... https://t.co/ubqxhkvmY7 https://t.co/NAAD62XjpY
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 7 months ago
ICYMI: Rinvoq FDA Approved for Active Psoriatic Arthritis
https://t.co/1ysUj0GUqw https://t.co/fmDA9UyFY3
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 7 months ago
🆕 Myositis Specific Antibodies (MSAs): Clinical Features and Treatment for #Myositis/IIM 💪🏽
💪🏻Proximal Muscle Weakness
🫁 Interstitial Lung Disease
🤚🏽 Cutaneous [Dermatomyositis]
#RheumTwitter #DermTwitter #PulmTwitter #MedEd https://t.co/TCwpLI1yNr
Mithu Maheswaranathan, MD @MithuRheum ( View Tweet )
4 years 7 months ago
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations https://t.co/ljqEjZNwx5 https://t.co/8fVIskV3gd
Pedro Machado @pedrommcmachado ( View Tweet )
4 years 7 months ago
ICYMI: Increased risk death in 310 scleroderma pts: 63 diffuse SSc, 279 limited dz & 33 sine scleroderma (SMR = 1.88). Reduced survival at 10 yrs (78%) & 15 yrs(61%). 69 deaths, 46% in diffuse PSS - due to ILD, PHA, and GI involvement https://t.co/OZg8QamhEB
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 7 months ago
There's good news and bad news in rheumatology fellowship matching for 2022. There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. All that a more on this week’s podcast.
https://t.co/gklOK2S1QC https://t.co/QrYg1QZKhJ
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 7 months ago
